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Supplement to Indian Heart Journal “Sudden Cardiac Death”.
In the event ATP is working by interrupting several times a VT
that is self relapsing before the episode is termed “termi-
nated”, ATP would be turned off if SMART were ON. This
would disable an effective therapy, possibly leading to shocks
on another bout of VT. Moreover, ATP efficacymay have some
variability in a given patient, especially during acute illnesses
such as pneumonia, hypokaliemia due to several different
reasons, acute ischemia, and other clinical situations. When
SMART mode was enabled, ATP might be turned off, and its
benefit lost (that means shock delivery occurrence) after the
acute situation has subsided. More than 50% of times devices
are not reprogrammed to the pre-existing settings after a
hospital admission. Therefore, being not proven that SMART
mode adds anything to ATP efficacy and/or safety and indeed
possibly disrupting its effectiveness, it should be kept off.
As Dr Reif has pointed out, stability is turned OFF in Med-
tronic andNayamed by shipment and in themanuscript figure
2. This is related to the way stability works in this manufac-
turer compared to others (see hints in the Appendix): stability
works as soon as the VT counter reaches 3, and resets it to
0 (holds counter in VF) when it is satisfied. In this way, it
ovverridesWavelet that is used only when the NID is reached.
While stability has never been prospectively studied by Med-
tronic for SVT discrimination in terms of sensitivity/specificity
to SVT andVT/VF,Wavelet has.Wavelet alone proves superior
to stability and onset working together. Based on these con-
siderations, it is wiser to use stability only after wavelet has
proven ineffective and the arrhythmia recording suggests a
potential benefit from stability (RR interval truly unstable).
Boston uses Rhythm ID or onset/stability in single chamber
devices, and as such this issue is out of debate. Indeed,
Rhythm ID is gatekeeper ahead of stability when V-rate is
equal/slower A-rate in dual chamber/CRT-D devices, thus it
can still be used for re-detection.
I agree that a second analysis during re-detection after ATP
has been delivered would help to restrict inappropriate ther-
apy delivery. What a clinician looks at after ATP has been
delivered is: atrium to ventricle pattern, QRS morphology,
interval stability. No manufacturer allows all these parame-
ters to be analyzed. The algorithms Dr. Reif refers to work bymaking use of atrial and ventricular patterns and of RR in-
terval stability after therapy one has been delivered, and to a
certain extent they can be successful. The main limitation of
these algorithms is that they are not applied to VF zone, thus
this latter has to be programmed atleast 200 bpm or faster to
reduce inappropriate shocks. Moreover, both algorithms need
placement of a second lead (save for Biotronik DX devices)
with related adverse events (see the PARADþ study). One
pivotal aspect in dual chamber analysis is recognition of far-
field R-wave sensing, that can potentially fool the algorithm
decision, and is not available in these manufacturers. In
literature, it is not known how many arrhthmias have been
correctly classified during re-detection, and it has to be
remembered that PARADþ and SMARTDetection studieswere
carried out with short detection times, thus the chance of self-
termination could also have inflated their efficacy. In the
practical ground, their data on SVT discrimination should be
confronted nowadays with the PAINFREE SST data showing
only 2.4% of single chamber ICD patients receiving inappro-
priate therapy delivery (Dr. Schloss at Athens, June 2013). A
comparison across manufacturers with similar arrhythmia
cutoffs and similar detection times could make possible an
estimate of the true clinical efficacy of these different algo-
rithms for SVT discrimination. Moreover, changes are going to
happen, since Biotronik is going to release new devices
featuring a Morphological discriminator on top of SMART
Detection to improve the efficiency of SVT discrimination.
This will open a new perspective, especially if that will be
available during re-detection.
I sincerely hope I addressed your observations. It has been
my pleasure reading your comments.
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